AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37339586
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus vorinostat (Vorinostat 100 mg twice a day for DL1 and 200 mg twice a day for DL2, administered orally from days 1 to 5 and 8 to 12; Pembrolizumab 200 mg IV every 3 weeks)
Trial: 37339979
Drug: GVAX vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX vaccine with low-dose cyclophosphamide (Arm A)
Trial: 37339979
Drug: GVAX vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX vaccine with anti-PD-1 antibody nivolumab (Arm B)
Trial: 37339979
Drug: GVAX vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX vaccine with nivolumab and anti-CD137 agonist antibody urelumab (Arm C)
Trial: 37340170
Drug: 4-session intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-session intervention including safety plans with mobile augmentation
Trial: 37340170
Drug: 4-session intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-session intervention including safety plans without mobile augmentation
Trial: 37340213
Drug: Dog-assisted Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog-assisted Therapy (DAT)
Trial: 37340306
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement + PFMT
Trial: 37340369
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy using surgical gloves
Trial: 37340397
Drug: Low-dose chemotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chemotherapy (Ara-C) administered at home by parents
Trial: 37340397
Drug: Home chemotherapy
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home chemotherapy intervention
Trial: 37340439
Drug: MI-oriented adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Trial: 37340439
Drug: CBT-oriented adjunctive
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Trial: 37340439
Drug: Both MI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both MI and CBT treatments
Trial: 37340664
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in anti-CMV antibody in seropositive girls
Trial: 37341243
Drug: IDP-126 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-126 gel (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Trial: 37341243
Drug: Dyad gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyad gels (1 of the 3 dyad gels, phase 2 only)
Trial: 37341530
Drug: Nanoparticle-mediated tissue-targeted
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoparticle-mediated tissue-targeted therapies
Trial: 37342080
Drug: RealConsent (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RealConsent (internet-based intervention) with 100% dosage
Trial: 37342775
Drug: 1-week auto-CPAP
RxNorm normalized name: Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week auto-CPAP treatment
Trial: 37343084
Drug: Microdialysis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdialysis and ambulatory fraction collector for measuring tissue adrenal steroids
Trial: 37343145
Drug: Tanezumab 20
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 20 mg
Trial: 37343625
Drug: 10-μg bimatoprost
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10-μg bimatoprost implant
Trial: 37344061
Drug: Oral lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lutein and zeaxanthin supplementation for three months
Trial: 37638838
Drug: Pecan-enriched diet
RxNorm normalized name: Pecan
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan-enriched diet (68 g of pecans/day)
Trial: 37344265
Drug: Ad26.COV2.S booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S booster dose (5 × 10^10 viral particles)
Trial: 37344474
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) plus weekly paclitaxel (80 mg/m2)
Trial: 37344474
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) plus flat-dose capecitabine
Trial: 37344582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ophthalmologists and DLA-RB
Trial: 37344751
Drug: Inhaled PUR1900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled PUR1900 (itraconazole) at doses up to 40 mg per day
Trial: 37344751
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg) co-administered with inhaled PUR1900
Trial: 37344789
Drug: Open Discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Discontinuation (OD)
Trial: 37344789
Drug: Hidden Discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hidden Discontinuation (HD)
Trial: 37344801
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration of 250 ml of crystalloid fluid
Trial: 37344895
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b at a dosing regimen of 250-350-500 μg
Trial: 37344895
Drug: Approved dosing
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approved dosing schema of ropeginterferon alfa-2b (starting dose of 100 µg)
Trial: 37344997
Drug: Oxycodone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.05 mg/kg
Trial: 37345196
Drug: Ruxolitinib (JAK1/JAK2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (JAK1/JAK2 inhibitor)
Trial: 37345256
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of autologous culture-expanded adipose-derived mesenchymal stem cells (ADMSCs)
Trial: 37345876
Drug: Bulevirtide 2
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 2 mg per day for 144 weeks
Trial: 37345876
Drug: Bulevirtide 10
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 10 mg per day for 144 weeks
Trial: 37345876
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for 48 weeks followed by bulevirtide 10 mg per day for 96 weeks)
Trial: 37345996
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention (acute HIV testing, contract partner notification (cPN), and social contact referral)
Trial: 37346899
Drug: Gothenburg Treatment
RxNorm normalized name: Hb Gothenburg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gothenburg Treatment for Gaming Disorder (GOT-TO-GO) manual; a 15-week cognitive behavioral therapy treatment for GD
Trial: 37347015
Drug: Osteoconductive scaffold
RxNorm normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoconductive scaffold augmentation at the femoral tunnel aperture
Trial: 37347015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with femoral fixation using cortical suspension fixation and secondary press-fit fixation
Trial: 37347370
Drug: Inhaled IFN-α2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled IFN-α2b 2.5 MIU twice daily for 10 days (n = 6)
Trial: 37347370
Drug: Inhaled IFN-α2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled IFN-α2b 5.0 MIU twice daily for 10 days (n = 6)
Trial: 37347370
Drug: Inhaled IFN-α2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled IFN-α2b (both doses)
Trial: 37347553
Drug: Antibody responses
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody responses
Trial: 37347913
Drug: In-home telehealth
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home telehealth cognitive behavioral treatment
Trial: 37347913
Drug: In-person cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person cognitive behavioral treatment
Trial: 37348019
Drug: Standard endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard endocrine treatment of physician's choice (TPC)
Trial: 37348272
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of optimal cardioprotective therapy at discharge
Trial: 37348348
Drug: 2-year icotinib
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-year icotinib (125 mg thrice daily)
Trial: 37348348
Drug: 1-year icotinib
RxNorm normalized name: nicotine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year icotinib (125 mg thrice daily)
Trial: 37348519
Drug: Omicron BA.1
RxNorm normalized name: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omicron BA.1 monovalent booster (50 μg)
Trial: 37348519
Drug: Omicron BA.1
RxNorm normalized name: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omicron BA.1 bivalent booster (50 μg)
Trial: 37348816
Drug: Intravenous ferumoxytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ferumoxytol (2 infusions of 510 mg approximately 7 days apart)
Trial: 37348817
Drug: Intravenous ferumoxytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ferumoxytol (2 infusions of 510 mg)
Trial: 37348817
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (325 mg twice daily)
Trial: 37349100
Drug: Pembrolizumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (4 mg/kg)
Trial: 37349747
Drug: Dentist-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentist-administered cognitive behavioural therapy (D-CBT, n=36)
Trial: 37349841
Drug: Pregabalin 25
RxNorm normalized name: pregabalin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 25 mg
Trial: 37350404
Drug: Post-extraction intravenous
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-extraction intravenous antibiotics
Trial: 37350404
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy duration
Trial: 37350492
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I measurement at presentation, threshold of 2 ng/L
Trial: 37350492
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I measurement at presentation, threshold of 5 ng/L
Trial: 37462028
Drug: Mechanical thrombectomy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Trial: 37350968
Drug: Atezolizumab with
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab with EC/EP for two cycles followed by concurrent palliative HFRT and two cycles of atezolizumab with EC/EP, then atezolizumab every 3 weeks for a maximum of 2 years.
Trial: 37350968
Drug: Concurrent hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent hypofractionated thoracic radiotherapy (HFRT) with immunochemotherapy.
Trial: 37350989
Drug: Nangibotide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nangibotide (1.0 mg/kg/h)
Trial: 37350990
Drug: Weight-adjusted intermediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted intermediate dose of low-molecular-weight heparin
Trial: 37350990
Drug: Fixed-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose of low-molecular-weight heparin
Trial: 37351456
Drug: Adintrevimab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adintrevimab (300 mg, single intramuscular injection)
Trial: 37351564
Drug: Orforglipron (12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orforglipron (12, 24, 36, or 45 mg)
Trial: 37351585
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (12 weeks acute phase and 16 weeks continuation phase)
Trial: 37351932
Drug: Guided Imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Imagery (GI) treatment delivered via telephone for smoking cessation.
Trial: 37351932
Drug: Standard evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard evidence-based behavioral treatment delivered via telephone.
Trial: 37352262
Drug: Tacrolimus/reduced-dose methotrexate/mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus/reduced-dose methotrexate/mycophenolate (mini-MTX/MMF)
Trial: 37352266
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg and brentuximab vedotin (BV) 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity.
Trial: 37352284
Drug: Structured Emotionally
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Emotionally Focused Family Therapy (EFFT)
Trial: 37352322
Drug: Nifurtimox 60-day
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox 60-day treatment regimen
Trial: 37352322
Drug: Nifurtimox 30-day
RxNorm normalized name: nifurtimox 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifurtimox 30-day treatment regimen
Trial: 37352498
Drug: pomalidomide 5
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pomalidomide 5 mg orally for 21 days of 28-day cycles for up to 1 year
Trial: 37353277
Drug: Continue disease-modifying
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue disease-modifying therapy
Trial: 37353277
Drug: Discontinue disease-modifying
RxNorm normalized name: Entex HC Discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue disease-modifying therapy
Trial: 37353278
Drug: Descartes-08 (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Descartes-08 (autologous anti-BCMA rCAR-T therapy)
Trial: 37353450
Drug: HepB-CpG vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HepB-CpG vaccine
Trial: 37353654
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment timing
Trial: 37353788
Drug: Tumour necrosis
RxNorm normalized name: Tumour necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour necrosis factor inhibitor (TNFi)
Trial: 37353795
Drug: Remotely delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely delivered TEACH program plus treatment as usual (TAU)
Trial: 37354546
Drug: Bempedoic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bempedoic acid, 180 mg daily (n=2100)
Trial: 37354554
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of daily low-dose hCG (260 IU recombinant hCG) administration before IVF/ICSI cycle
Trial: 37354976
Drug: Lactase nonpersistent
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase nonpersistent (LNP) individuals consuming more than 12.46 g/d
Trial: 37355035
Drug: Technology-assisted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technology-assisted intervention (12-week program including 3 center-based supervised exercise sessions, a fitness watch, 6 educational videos, and weekly video calls)
Trial: 37355043
Drug: efinopegdutide 10
RxNorm normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efinopegdutide 10 mg weekly
Trial: 37355043
Drug: semaglutide 1
RxNorm normalized name: semaglutide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1 mg weekly
Trial: 37355263
Drug: Multimodal occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal occupational therapy including patient education, hand exercises, assistive devices and orthoses (n=90)
Trial: 37355267
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment - identical-looking cuff placed around the arm but not inflated.
Trial: 37356033
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg pegozafermin weekly
Trial: 37356033
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pegozafermin weekly
Trial: 37356033
Drug: 44 mg
RxNorm normalized name: caffeine 44 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mg pegozafermin once every 2 weeks
Trial: 37356038
Drug: Crizanlizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizanlizumab (5 mg/kg) plus standard of care
Trial: 37356066
Drug: Combined clinically
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined clinically significant or severe hypoglycemia with insulin icodec
Trial: 37356066
Drug: Combined clinically
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined clinically significant or severe hypoglycemia with insulin glargine U100
Trial: 37356078
Drug: Ripretinib as
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib as a fourth-line treatment
Trial: 37356561
Drug: Lozenge containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge containing Lacticaseibacillus rhamnosus, LGG® (DSM33156), Lactobacillus paracasei subsp. paracasei, L. CASEI 431® (DSM33451) and prebiotic (arginine 2%)
Trial: 37356561
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge without arginine or probiotics
Trial: 37356618
Drug: Impact on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact on daily life
Trial: 37356632
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) application, 1.25 g of TXA powder sprayed endoscopically on the ulcer, alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Trial: 37356632
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (no TXA), alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Trial: 37356632
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) application
Trial: 37356634
Drug: US capsule
RxNorm normalized name: DIM-plus Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US capsule endoscopy (USCE)